Trial Profile

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2023 Baseline demographics and clinical characteristics of patients from NCT03546621, NCT02888106, NCT03852433 and NCT03852719, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
27 Apr 2023 Results published in the Journal of Hepatology
01 Jan 2023 Results (n=171; Between Feb 16, 2016, and Dec 8, 2016) assessing the antiviral activity of bulevirtide in patients chronically infected with hepatitis B virus and hepatitis D virus, published in The Lancet Infectious Diseases.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com